Evidence map›Paper›PMID 24814489›Full record

ArticleJournal of the American College of Cardiology2014

Curing atherosclerosis should be the next major cardiovascular prevention goal.

Jennifer G Robinson, Samuel S Gidding

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in Journal of the American College of Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03393377. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03393377 nacompleted

Preventive Arterial Wall Phenotype in Subjects at Moderate Cardiovascular Risk Induced by Very Low-dose Fluvastatin/Valsartan Combination: a Pilot Study

Ran2014Enrolled20Registered outcomes19Posted comparisons0ConditionsAtherosclerosisArmsfluvastatin 10 mg and valsartan 20 mg, Placebo
PMID 27040132PMID 28012835PMID 22385885PMID 20338492PMID 24263076PMID 28870631PMID 27222591PMID 28408026PMID 26567372other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jennifer G RobinsonDepartments of Epidemiology and Medicine, University of Iowa, Iowa City, Iowa. Electronic address: jennifer-g-robinson@uiowa.edu.
Samuel S GiddingDivision of Cardiology, Nemours Cardiac Center/A. I. DuPont Hospital for Children, Wilmington, Delaware; Department of Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania.
DuPont (United States) · USUniversity of Iowa · US

Funding

Delaware Clinical and Translational Research ACCEL Program (TEVAL Core)U54GM104941 · UNIVERSITY OF DELAWARE · 2025 to 2025
$3.2M
NIGMS NIH HHS U54 GM104941
6 · The paper itself

Abstract

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in developed and developing countries. Despite decades of effort, unhealthy lifestyle habits and ASCVD risk factor levels remain high and are increasing in many population groups. A new approach to ASCVD prevention is needed. Multiple lines of evidence from animal and human studies suggest that atherosclerosis regression and normalization of vessel function can occur when low-density lipoprotein cholesterol (LDL-C) lowering occurs early in the course of atherosclerosis or when very aggressive LDL-C lowering occurs somewhat later. We propose a new paradigm focused on curing atherosclerosis early in the course of the disease. An approach that resets the vascular aging clock composed of initial regression therapy followed by periodic retreatment to suppress atherosclerosis development may be possible, with the ultimate goal of preventing subsequent ASCVD events. Proof-of-concept studies are needed to determine: 1) the optimal age and/or extent of atherosclerosis for intervention and LDL-C-lowering therapy; 2) the intensity and duration of therapy for inducing atherosclerosis regression; and 3) documenting the normalization of vascular function. Ultimately, this new paradigm will need to be evaluated in ASCVD outcomes trials.

Indexed as

Decision MakingAtherosclerosisCardiovascular AgentsHumansPrimary PreventionCardiovascular Agentsatherosclerosisprimordial preventionregression

Identifiers

PMID24814489
OpenAlexW2064407018

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.